Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Apr;76(1):8-12.

Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin

N D Garbett  1 , C S Munro, P J Cole
Affiliations

Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin

N D Garbett et al. Clin Exp Immunol. 1989 Apr.

Abstract

Standard preparations of immunoglobulin for intravenous use consist predominantly of IgG (greater than 95%). We have compared the ability of a standard preparation (Sandoglobulin) with that of a new preparation (Pentaglobin, containing 12% IgM and 12% IgA) to improve the opsonic activity of antibody-deficient human sera in vitro. Panhypogammaglobulinaemic sera were poorly opsonic for five of six organisms tested, particularly Pseudomonas aeruginosa, Escherichia coli and Streptococcus pneumoniae, but opsonized Staphylococcus aureus almost normally. Both immunoglobulin preparations significantly improved the opsonic activity of the antibody-deficient sera for most organisms. The major difference between the two preparations was the ability of Pentaglobin to supply opsonins for P. aeruginosa, E. coli and Klebsiella pneumoniae, while Sandogloblin was significantly more potent in opsonins for Haemophilus influenzae. Pentaglobin demonstrates significant in vitro opsonic activity, particularly for enterobacteria (coliforms) and P. aeruginosa. Its content of IgM antibodies appears to confer special properties on Pentaglobin not seen with standard preparations of immunoglobulin for intravenous use. Its place in clinical practice remains to be determined but it may have a possible role in augmenting host defence mechanisms in Gram-negative septicaemia.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Infect Immun. 1977 Jun;16(3):796-804 - PubMed
    1. J Clin Invest. 1976 Jul;58(1):190-9 - PubMed
    1. J Clin Invest. 1979 Feb;63(2):276-86 - PubMed
    1. Lancet. 1979 Nov 10;2(8150):977-82 - PubMed
    1. Immunology. 1980 Dec;41(4):903-11 - PubMed

Publication types

MeSH terms

LinkOut - more resources